The pharmaceutical company Mylan has developed a reputation for fighting tooth-and-nail to promote its flagship product, the EpiPen.
Mylan has contended that its intensive marketing efforts save lives. But over the past year, the public has started to question whether the company’s business tactics are in line with the best interests of patients.
Now STAT has learned of yet another previously unreported legal maneuver employed by the company to force one state to drive even more sales to its EpiPen, an epinephrine auto-injector used to halt potentially life-threatening allergic reactions.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect